Physician profile
Carlos Ramirez Mejia
NPI 1053375360
$24,607.83
in general payments reported to CMS, 2019-2025
74 companies · $3,966 in 2025
The $3,966 reported for 2025 was more than what 87% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,333 · 2020: $1,564 · 2021: $1,834 · 2022: $3,516 · 2023: $4,775 · 2024: $5,620 · 2025: $3,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,296.72 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,312.06 | 2021-2025 | |
| Ucb, INC. | $1,902.30 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Teva Pharmaceuticals USA, INC. | $1,587.27 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $1,078.00 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Amgen INC. | $1,069.64 | 2019-2025 | Uplizna |
| Pfizer INC. | $1,019.95 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $786.23 | 2019-2025 | |
| Lundbeck LLC | $778.21 | 2021-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $734.81 | 2019-2025 | Ultomiris |
| Neurelis, INC. | $713.34 | 2020-2025 | Valtoco |
| Scilex Pharmaceuticals INC. | $699.54 | 2019-2025 | Ztlido |
| Eisai INC. | $628.39 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $524.79 | 2019-2025 | Nuplazid |
| Biogen, INC. | $512.75 | 2019-2025 | Vumerity, Skyclarys |
| Sk Life Science, INC. | $457.57 | 2021-2025 |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $434.54 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $434.50 | 2021-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $417.13 | 2019-2024 | Gocovri, Apokyn |
| Genzyme Corporation | $390.92 | 2019-2022 | |
| Harmony Biosciences LLC | $390.32 | 2023-2025 | Wakix |
| Kyowa Kirin, INC. | $355.50 | 2019-2024 | Nourianz |
| Otsuka America Pharmaceutical, INC. | $350.35 | 2023-2025 | Rexulti, Nuedexta |
| Sunovion Pharmaceuticals INC. | $345.70 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $286.17 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| Biohaven Pharmaceutical Holding Company Ltd. | $265.17 | 2022 | |
| Supernus Pharmaceuticals, INC. | $259.80 | 2019-2022 | |
| Boston Scientific Corporation | $245.39 | 2019-2025 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $194.18 | 2020-2023 | Onpattro |
| Acorda Therapeutics, INC | $192.96 | 2019-2024 | Inbrija, Ampyra |
| Azurity Pharmaceuticals, INC. | $181.14 | 2023-2025 | Horizant, Horizant |
| Avanir Pharmaceuticals, INC. | $173.34 | 2019-2022 | |
| Argenx US, INC. | $172.19 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $161.62 | 2021-2025 | Rytary, Crexont, Ongentys |
| Tanabe Pharma America, INC. | $151.41 | 2020-2025 | Radicava |
| Ge Healthcare | $147.54 | 2019-2025 | |
| Emd Serono, INC. | $143.53 | 2019-2023 | Mavenclad |
| Astrazeneca Pharmaceuticals Lp | $143.35 | 2023-2025 | Wainua |
| Idorsia Pharmaceuticals US INC | $135.93 | 2022-2024 | Quviviq |
| Csl Behring | $135.59 | 2019-2023 | Hizentra |
| Adamas Pharmaceuticals, INC. | $132.32 | 2019-2021 | |
| Akcea Therapeutics, INC. | $121.35 | 2019 | |
| Corium, LLC | $116.80 | 2023-2025 | Adlarity, Azstarys |
| Biohaven Pharmaceuticals, INC. | $93.31 | 2021 | |
| Averitas Pharma INC. | $72.37 | 2023 | Qutenza |
| Upsher-Smith Laboratories LLC | $70.91 | 2019-2022 | |
| Zyla Life Sciences, INC. | $65.26 | 2019-2020 | |
| Alfasigma USA, INC. | $61.04 | 2021-2022 | |
| Avion Pharmaceuticals | $60.33 | 2022-2023 | Dhivy |
| Genentech USA, INC. | $59.25 | 2019-2025 | Ocrevus |
| Livanova USA, INC. | $59.18 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Almatica Pharma LLC | $57.23 | 2021-2023 | Loreev Xr |
| C2n Diagnostics, LLC | $56.05 | 2025 | Precivityad2 |
| Insightec,INC | $55.32 | 2025 | Exablate |
| Aprecia Pharmaceuticals, LLC | $50.09 | 2022 | |
| Inspire Medical Systems, INC. | $48.89 | 2024 | Inspire |
| Vertical Pharmaceuticals, LLC | $45.35 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.87 | 2023 | Gammagard |
| Sumitomo Pharma America, INC. | $41.71 | 2023 | Aptiom |
| Shire North American Group INC | $38.30 | 2019 | |
| Arbor Pharmaceuticals, INC. | $37.38 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $35.10 | 2024 | |
| Assertio Therapeutics, INC. | $31.42 | 2019-2020 | |
| Life Molecular Imaging Ltd | $26.94 | 2019-2023 | Neuraceq |
| Axsome Therapeutics, INC. | $25.50 | 2025 | Symbravo |
| Janssen Biotech, INC. | $24.64 | 2025 | |
| Aquestive Therapeutics, INC. | $23.24 | 2021 | |
| Revance Therapeutics, INC. | $22.37 | 2024 | Daxxify |
| Tris Pharma INC | $21.67 | 2025 | Dyanavel Xr |
| Springworks Therapeutics, INC. | $20.53 | 2025 | |
| Banner Life Sciences, LLC | $17.02 | 2023 | |
| Promius Pharma LLC | $16.25 | 2019 | |
| Celgene Corporation | $14.98 | 2025 | Zeposia |
| Currax Pharmaceuticals LLC | $14.45 | 2020 | |
| Nevro Corp. | $13.29 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Ramirez Mejia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.